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Summary 
Background An increasing number of countries with low incidence of tuberculosis have pre-entry screening 
programmes for migrants. We present the ﬁ rst estimates of the prevalence of and risk factors for tuberculosis in 
migrants from 15 high-incidence countries screened before entry to the UK.
Methods We did a population-based cross-sectional study of applicants for long-term visas who were screened for 
tuberculosis before entry to the UK in a pilot programme between Oct 1, 2005, and Dec 31, 2013. The primary outcome 
was prevalence of bacteriologically conﬁ rmed tuberculosis. We used Poisson regression to estimate crude prevalence 
and created a multivariable logistic regression model to identify risk factors for the primary outcome.
Findings 476 455 visa applicants were screened, and the crude prevalence of bacteriologically conﬁ rmed tuberculosis 
was 92 (95% CI 84–101) per 100 000 individuals. After adjustment for age and sex, factors that were strongly associated 
with an increased risk of bacteriologically conﬁ rmed disease at pre-entry screening were self-report of close or 
household contact with an individual with tuberculosis (odds ratio 11·6, 95% CI 7·0–19·3; p<0·0001) and being an 
applicant for settlement and dependant visas (1·3, 1·0–1·6; p=0·0203). 
Interpretation Migrants reporting contact with an individual with tuberculosis had the highest risk of tuberculosis at 
pre-entry screening. To tackle this disease burden in migrants, a comprehensive and collaborative approach is needed 
between countries with pre-entry screening programmes, health services in the countries of origin and migration, 
national tuberculosis control programmes, and international public health bodies.
Funding Wellcome Trust, Medical Research Council, and UK National Institute for Health Research.
Copyright © Aldridge et al. Open Access article distributed under the terms of CC BY.
Introduction
Medical screening of migrants for tuberculosis has been 
implemented for more than a century, but only recently 
have data been systematically obtained and analysed to 
understand its eﬀ ectiveness.1–3 Screening can occur 
before entry (ie, pre-entry screening), at entry (sometimes 
called port-of-entry screening), or after entry. Australia, 
Austria, Canada, France, Israel, Jordan, New Zealand, the 
UK, and the USA have pre-entry screening programmes 
for tuberculosis.4 In our 2014 systematic review and 
meta-analysis,2 we identiﬁ ed substantial variation in 
protocols and detection rates of active infection, but the 
detection rates were in migrants from high-incidence 
countries. No UK data were included in this review. 
Historically, the UK screened migrants before, at, and 
after entry.5 In May, 2012, the UK Government announced 
the transition to a fully pre-entry system, expanding the 
screening programme from 15 pilot locations in 
operation from 2005, to 101 high-incidence countries (ie, 
those with a WHO-estimated prevalence of >40 cases per 
100 000 population). This transition occurred in four 
phases and was completed on March 31, 2014 (appendix 
p 9). To improve international pre-entry screening 
programmes, we investigated the prevalence of and risk 
factors for tuberculosis in migrants from high-incidence 
countries screened before migration, using historical 
data from the 15 countries in the UK pilot programme.
Methods 
Study design 
We did a population-based cross-sectional study of 
migrants applying for visas to stay in the UK for more 
than 6 months, who were screened for tuberculosis before 
entry in 15 countries taking part in a pilot programme. We 
used data collected by the International Organization for 
Migration (IOM) between Oct 1, 2005, and Dec 31, 2013, 
on behalf of the UK as part of the screening process and 
included demographic and clinical data for all individuals 
screened, including age, sex, self-report of close or 
household contact with an individual with tuberculosis 
before screening (deﬁ ned as anyone in the household who 
has been diagnosed with tuberculosis in the past 2 years, 
or history of recent contact with an individual with active 
pulmonary tuberculosis who shared the same enclosed air 
space, household, or other enclosed environment for a 
prolonged period of days or weeks; appendix p 4), visa 
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category, and whether the individual was screened at a 
clinic where culture testing was done. Data were obtained, 
collated, and cleaned by the IOM Health Research and 
Epidemiology Unit and Public Health England to ensure 
that records included all laboratory results of individuals 
screened. Data for WHO prevalence in migrants’ country 
of origin were from 2010.6
During the pilot phase of the pre-entry screening 
programme, culture testing for Mycobacterium tuberculosis 
was not available at all sites. To ensure comparability of 
estimates across countries and locations, we restricted the 
primary analysis to data from sites where culture and smear 
testing was done on all sputum samples. We removed 
duplicate screens according to rules in appendix p 3.
Ethics approval was received for this analysis from 
University College London Research Ethics Committee 
(3294/002). Public Health England has authority under 
the Health and Social Care Act 2012 to hold and analyse 
national surveillance data (including tuberculosis pre-
entry screening programme data) for public health and 
research purposes.
Procedure 
The UK tuberculosis technical instructions set out 
procedures for  screening, with quality assurance provided 
by Public Health England. Brieﬂ y, applicants aged 11 years 
or above received standard posteroanterior chest radio-
graphy, and all individuals with radiological ﬁ ndings 
consistent with tuberculosis were required to undergo 
sputum testing (appendix p 1). Applicants who were un-
willing or unable to have radiography (eg, pregnant women) 
were required to provide sputum specimens taken on three 
separate occasions, not less than 24 h apart and ideally in 
the early morning. Specimens were tested for M tuberculosis 
in designated laboratories by smear and culture. All 
specimens were examined under the micro scope for acid-
fast bacilli by an auramine stain (or, if necessary, by 
Ziehl-Neelsen stain). Specimens were cultured for a 
minimum of 6 weeks in liquid media or 8 weeks in solid 
media, unless a positive result was obtained earlier than 
these time periods. If no growth was detected after these 
time periods, specimens were reported as negative. 
Applicants were issued with a clearance certiﬁ cate if 
their chest radiographs were classiﬁ ed as free of any 
radiological changes, or had minor ﬁ ndings that were 
not associated with tuberculosis. Individuals diagnosed 
with active tuberculosis could restart the screening 
process after successful completion of a full course of 
approved treatment, but not within 6 months of the 
original screening examination. 
Outcomes 
The primary outcome was the prevalence of bacterio-
logically conﬁ rmed tuberculosis, with cases speciﬁ ed 
according to a WHO-revised deﬁ nition of “one from whom 
a biological specimen is positive by smear microscopy or 
culture”.7 Secondary outcomes were prevalence of 
tuberculosis conﬁ rmed by culture testing on liquid or solid 
Research in context
Evidence before this study
In 2014, we did a systematic review and meta-analysis of 
pre-entry screening for tuberculosis, which we have updated to 
identify new articles published until Nov 19, 2015, by searching 
Medline and Embase with the same search terms, including 
“migrants”, “pre-entry screening”, and “tuberculosis”. Only studies 
reporting culture-positive results by country were included in this 
updated review and meta-analysis. Prevalence ranged from 
19·7 (95% CI 10·3–31·5) cases identiﬁ ed per 100 000 individuals 
screened in countries with a prevalence of 50–149 cases per 
100 000, to 335·9 (283·0–393·2) per 100 000 in countries with a 
prevalence of greater than 350 per 100 000. Substantial variation 
exists in the screening protocols used by each study.
Added value of this study
Migrants with a history of close or household contact with an 
individual with tuberculosis were at an increased risk of being 
detected with bacteriologically conﬁ rmed infection at pre-entry 
screening. We present direct estimates of the yield of 
tuberculosis in applicants for student visas (85 [95% CI 75–96] 
cases per 100 000 individuals); although the risk of tuberculosis 
in students is lower than the overall detection rate, students 
account for a large number of cases in many low-incidence 
countries. Our results will enable further examination of the 
cost-eﬀ ectiveness of screening of this group, with operational 
data from a large number of student visa applicants. We 
updated a meta-analysis of culture-positive cases by country of 
origin to include data from our study from all countries where 
more than 1000 migrants had been screened. Compared with 
the 2014 meta-analysis, the level of heterogeneity increased, 
and the prevalence of tuberculosis detected no longer increased 
with WHO prevalence of tuberculosis in the country of origin. 
Implications of all the available evidence
Present evidence supports the case for contact tracing and 
investigation in the country of origin, and improved 
coordination between pre-entry screening programmes and 
national tuberculosis programmes in the applicant’s country, 
both of which are an increasing focus of both the UK and the 
USA. Our study provides additional support for recent changes 
to pre-entry screening policies in these two countries, since 
migrants screened at sites with sputum culture testing were 
more likely to be detected with active pulmonary tuberculosis, 
after adjustment for age and sex, than those screened at sites 
without such testing. To tackle the burden of tuberculosis in 
migrants, a wide-ranging approach that includes screening and 
treatment for latent tuberculosis infection, in addition to the 
existing focus on active disease, will be necessary.
For the UK tuberculosis 
technical instructions see 
https://www.gov.uk/
government/publications/uk-
tuberculosis-technical-
instructions
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media; tuberculosis conﬁ rmed by microscopy for acid-fast 
bacilli; tuberculosis conﬁ rmed by culture testing on liquid 
or solid media and resistant to one or more anti-tuberculosis 
drugs; and clinically conﬁ rmed tuberculosis.
Statistical analysis
We used Poisson regression (suitable for modelling of rare-
event data) to estimate crude prevalence of the primary 
and secondary outcomes, calculated per 100 000 individuals 
screened. We also calculated estimates of prevalence 
adjusted by age and sex for the primary and secondary 
outcomes, and compared adjusted estimates for each 
country with WHO population prevalence in 2010.6 To 
account for duplicate screens of visa applicants, all crude 
and adjusted estimates accounted for clustering by 
individual. We estimated the number needed to screen to 
detect one case as the inverse of screening prevalence, 
under the assumption of a comparator of no tuberculosis 
screening. We built a multivariable logistic regression 
model to identify risk factors for the primary outcome, and 
present ﬁ nal results of this model as odds ratios (ORs), 
with 95% CIs and p values. We estimated population 
attributable fractions (appendix p 8) with multivariable 
models, and interpreted the results as the proportion of 
incident tuberculosis attributable to each risk factor, after 
controlling for each other and for known confounders. We 
used Stata version 13 for all statistical analyses.
Our main analysis included migrants screened at sites 
where culture and smear testing was done on all sputum 
samples. Sensitivity analysis included all migrants 
screened before entry by the IOM, irrespective of whether 
culture testing was available at the screening site, to 
examine the eﬀ ect of the introduction of sputum testing 
on the prevalence of bacteriologically conﬁ rmed cases of 
tuberculosis. At the start of the pilot programme, culture 
testing was not universally available at IOM screening 
clinics. As a secondary analysis, we used multivariable 
logistic regression to examine whether the introduction of 
culture testing was associated with an increased risk of 
bacteriologically conﬁ rmed tuberculosis after controlling 
for age, sex, WHO prevalence in the country of origin, 
self-report of close or household contact with a case of 
tuberculosis before screening, and visa category.
We also updated our previous systematic review and 
meta-analysis of pre-entry screening for tuberculosis.2 
Additional details on the method used are provided in 
appendix p 5.
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
692 362 visa applicants screened 
 106 duplicate records
215 801 applicants screened at sites that did not 
 have sputum culture testing 
6232 did not have chest radiography
476 455 included in analysis 
470 223 had chest radiography
21 772 had sputum samples tested*
19 452 had chest radiography
19 426 compatible with tuberculosis
19 had no abnormality
7 abnormality not tuberculosis
2318 pregnant women
2 unwilling to have chest radiography
 Figure 1: Results of the screening process between Oct 1, 2005, and Dec 31, 
2013, in countries with screening by the International Organization 
for Migration
*Sputum testing was not done in 3911 children and <5 pregnant women.
 n Prevalence per 100 000 individuals screened
Bacteriologically conﬁ rmed cases Culture-positive cases Smear-positive cases
All 476 455 (100%) 92 (84–101) 83 (75–92) 55 (49–62)
Age (years)
0–15 18 729 (3·9%) 37 (18–78) 37 (18–78) 11 (3–43)
16–44 444 579 (93·3%) 92 (83–101) 83 (75–92) 53 (47–60)
45–64 10 413 (2·2%) 134 (80–227) 115 (65–203) 163 (102–262)
≥65 2734 (0·6%) 329 (172–631) 293 (147–584) 256 (122–536)
Sex
Female 167 393 (35·1%) 116 (101–134) 108 (93–125) 83 (70–98)
Male 309 062 (64·9%) 79 (70–90) 70 (61–80) 40 (33–47)
Close or household contact with an individual with tuberculosis
No 475 216 (99·7%) 89 (81–98) 80 (72–88) 53 (47–60)
Yes 1239 (0·3%) 1372 (855–2201) 1211 (732–2003) 726 (379–1393)
(Table 1 continues on next page)
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writing of the report. The corresponding author had 
full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
Between Oct 1, 2005, and Dec 31, 2013, 692 362 visa 
applicants were screened for tuberculosis (ﬁ gure 1). 
After exclusion of duplicate records and applicants 
screened at sites that did not have culture testing of 
sputum, 476 455 screening records were included in the 
analysis, with 470 223 chest radiographs undertaken and 
sputum samples collected from 21 772 applicants. Chest 
radio graphs were not done in 3911 children and 
2319 pregnant women. 
439 cases of bacteriologically conﬁ rmed tuberculosis 
were diagnosed, providing a crude prevalence of 
92 (95% CI 84–101) per 100 000 screened (table 1). The 
 n Prevalence per 100 000 individuals screened
Bacteriologically conﬁ rmed cases Culture-positive cases Smear-positive cases
(Continued from previous page)
Visa category
Student 281 703 (59·1%) 85 (75–96) 76 (66–86) 52 (44–61)
Settlement and dependant 160 436 (33·7%) 108 (93–125) 99 (85–116) 60 (49–73)
Work 14 748 (3·1%) 88 (51–152) 68 (36–126) 102 (61–169)
Working holiday maker 7380 (1·5%) 81 (37–181) 81 (37–181) 14 (2–96)
Family reunion 3389 (0·7%) 59 (15–236) 59 (15–236) 0 (0–0)
Other 8799 (1·8%) 68 (31–152) 57 (24–136) 45 (17–121)
Chest radiography*
No abnormality† 443 169 (94·2%) ·· ·· ··
Compatible with tuberculosis 19 654 (4·2%) 2234 (2036–2450) 2010 (1822–2216) 1308 (1158–1476)
Abnormality not tuberculosis 7400 (1·6%) ·· ·· ··
WHO prevalence (per 100 000) of tuberculosis in country of screening
40–149 18 910 (4·0%) 32 (14–71) 11 (3–42) 26 (11–64)
150–349 67 574 (14·2%) 225 (192–264) 223 (190–263) 200 (169–236)
≥350 389 971 (81·8%) 72 (64–81) 62 (55–70) 31 (26–37)
Year of examination
2007 5489 (1·2%) 146 (73–291) 128 (61–267) 109 (49–243)
2008 34 343 (7·2%) 166 (128–215) 154 (118–202) 122 (90–165)
2009 116 899 (24·5%) 87 (72–106) 71 (57–88) 67 (53–83)
2010 109 356 (23·0%) 68 (54–85) 56 (43–72) 47 (35–61)
2011 97 455 (20·5%) 87 (71–108) 82 (66–102) 33 (23–46)
2012 62 338 (13·1%) 106 (83–135) 103 (80–131) 59 (43–82)
2013 50 575 (10·6%) 93 (70–124) 93 (70–124) 32 (19–52)
Country of screening
Burkina Faso 73 (0·02%) ·· ·· ··
Bangladesh 143 154 (30·0%) 85 (71–101) 77 (64–93) 39 (30–51)
Cambodia 621 (0·1%) 161 (23–1144) 161 (23–1144) ··
CÔte d’Ivoire 1026 (0·2%) ·· ·· ··
Eritrea 152 (0·03%) 658 (92–4684) ·· 658 (92–4684)
Ghana 18 649 (3·9%) 32 (14–72) 11 (3–43) 27 (11–64)
Kenya 12 867 (2·7%) 101 (59–174) 101 (59–174) 39 (16–93)
Laos 193 (0·04%) ·· ·· ··
Niger 36 (0·01%) ·· ·· ··
Pakistan 243 243 (51·1%) 63 (54–74) 52 (44–62) 26 (20–33)
Sudan 4025 (0·8%) 25 (4–176) 25 (4–176) ··
Somalia 2760 (0·6%) 181 (76–435) 145 (54–386) 109 (35–337)
Togo 188 (0·04%) ·· ·· ··
Tanzania 4166 (0·9%) 120 (50–288) 120 (50–288) 24 (3–170)
Thailand 45 302 (9·5%) 291 (245–346) 291 (245–346) 283 (238–336)
Data are n (%) or prevalence (95% CI). *6232 applicants were unable or unwilling to have chest radiography. †No abnormality, or abnormality classiﬁ ed in groups 1, 2, and 3. 
Table 1: Baseline characteristics of applicants screened for tuberculosis and prevalence of primary and secondary outcomes, 2007–13
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number needed to screen to detect one case in this pilot 
programme was 1087 (990–1190). The crude prevalence 
of clinically diagnosed cases, excluding laboratory 
conﬁ rmed cases, was 3 (2–4) per 100 000. The overall 
prevalence of culture-conﬁ rmed samples with resistance 
to one or more tuberculosis drugs was 3 (2–5) per 
100 000 applicants screened or 5 (1·18%) of 422 culture-
conﬁ rmed samples that underwent drug susceptibility 
testing. 
Crude prevalence of bacteriologically conﬁ rmed 
tuberculosis was highest in migrants from countries 
with a WHO-estimated prevalence of 150–349 per 100 000 
(225 [192–264] per 100 000), and screening of 444 (379–521) 
applicants was necessary to detect one case. By contrast, 
crude prevalence of these cases was lower in migrants 
from countries with WHO-estimated prevalence of more 
than 350 per 100 000 (72 [64–81] per 100 000). 
In Eritrea and Tanzania, age-adjusted and sex-adjusted 
estimates for prevalence of bacteriologically conﬁ rmed 
tuberculosis in screened visa applicants were consistent 
with WHO-estimated population prevalence in 2010 
(ﬁ gure 2; see crude rates in appendix p 10). Compared 
with WHO population prevalence, age-adjusted and sex-
adjusted prevalence estimates of such cases were higher 
in Thailand and lower in all other countries.  
Multivariable logistic regression analysis (table 2) 
showed strong evidence that, after adjustment for age, 
sex, and clustering by individual, having close or 
household contact with an individual with tuberculosis 
was associated with an increased risk of bacteriologically 
conﬁ rmed tuberculosis at pre-entry screening (OR 11·6, 
95% CI 7·0–19·3; p<0·0001), with a population 
attributable fraction of 2·68%. Compared with migrants 
from countries with a WHO prevalence of 150–349 per 
100 000, migrants from countries with a prevalence of 
40–149 per 100 000 were at reduced risk of bacteriologically 
conﬁ rmed tuberculosis at pre-entry screening (0·1, 
0·1–0·3; p<0·0001), as were those from countries with a 
prevalence greater than 350 per 100 000 (0·3, 0·3–0·4; 
p<0·0001), after adjustment for age and sex. 
We did a sensitivity analysis to examine the prevalence 
of the primary and secondary outcomes when including 
all migrants screened before entry, not only those 
attending clinics where culture and smear testing was 
done on all sputum samples. 692 232 migrants were 
screened under this protocol, and the overall prevalence 
of bacteriologically conﬁ rmed tuberculosis was 75 (69–82) 
per 100 000 applicants screened (appendix p 6), which was 
lower than that in our primary analysis, but increased 
over time. 
In multivariable analysis adjusted for age, sex, WHO 
prevalence in country of origin, self-report of close or 
household contact with a case of tuberculosis before 
screening, and visa category, migrants screened at sites 
where sputum culture testing was done on all samples 
were associated with increased odds of having 
bacteriologically conﬁ rmed tuberculosis (OR 2·4, 1·9–3·0, 
p<0·0001; table 3), compared with those being screened at 
sites where culture testing was not routinely done. 
We updated our 2014 meta-analysis2 to compare our 
study results with published work. Our updated search 
identiﬁ ed 257 new studies, but none met the full 
inclusion criteria. Inclusion of crude estimates from the 
UK with data from published work8–13 increased the level 
of heterogeneity, and the prevalence of culture-positive 
cases no longer increased with the prevalence of 
tuberculosis in the country of origin (ﬁ gure 3). The 
summary estimates of culture-conﬁ rmed cases were 
Univariable OR Multivariable OR p value
Age (years)
0–15 0·4 (0·2–0·9) 0·3 (0·2–0·7) 0·0045
16–44 1·0 1·0 ··
45–64 1·5 (0·9–2·5) 1·2 (0·7–2·0) 0·56
≥65 3·6 (1·9–6.9) 3·2 (1·6–6.3) 0·0007
Sex
Female 1·0 1·0 ··
Male 0·7 (0·6–0·8) 1·0 (0·8–1·3) 0·73
Close or household contact with an individual with tuberculosis
No 1·0 1·0 ··
Yes 15·7 (9.6–25·5) 11·6 (7.0–19.3) <0·0001
Visa category
Student 1·0 1·0 ··
Settlement and dependant 1·3 (1·0–1·5) 1·3 (1·0–1·6) 0·0203
Work 1·0 (0·6–1·8) 0·9 (0·5–1·6) 0·73
Working holiday maker 1·0 (0·4–2·2) 1·2 (0·5–2·8) 0·63
Family reunion 0·7 (0·2–2·8) 0·4 (0·1–1·7) 0·21
Other 0·8 (0·4–1·8) 0·9 (0·4–2·1) 0·84
WHO prevalence (per 100 000) of tuberculosis in country of screening
40–149 0·1 (0·1–0·3) 0·1 (0·1–0·3) <0·0001
150–349 1·0 1·0 ··
≥350 0·3 (0·3–0·4) 0·3 (0·3–0·4) <0·0001
Data are OR (95% CI), unless otherwise indicated. OR=odds ratio.
Table 2: Risk factors for bacteriologically conﬁ rmed tuberculosis, 2007–13
0
200
400
600
800
1000
Pr
ev
al
en
ce
 p
er
 1
00
 0
00
 p
op
ul
at
io
n
Bu
rki
na
 Fa
so
Ba
ng
lad
esh
Ca
mb
od
ia
Cô
te 
d’I
vo
ire
Eri
tre
a
Gh
an
a
Ke
ny
a
Lao
s
Ni
ge
r
Pa
kis
tan
Su
da
n
So
ma
lia
To
go
Ta
nz
an
ia
Th
ail
an
d
WHO population prevalence in 2010 
Bacteriologically confirmed cases
Culture-positive cases
 Figure 2: Age-adjusted and sex-adjusted prevalence of bacteriologically conﬁ rmed and culture-positive 
tuberculosis at pre-entry screening, compared with 2010 WHO population prevalence estimates
Error bars on WHO prevalence estimates in 2010 represent the highest and lowest estimates for each country 
between 2007 and 2013. Error bars on bacteriologically conﬁ rmed and culture-positive cases represent 95% CIs. 
CIs are limited to a maximum of 1000 per 100 000 population for convenience of plotting.
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highest in countries with WHO prevalence of 150–249 
per 100 000 (192 [170–216] per 100 000 individuals 
screened).
Discussion
Nearly 700 000 pre-entry screening episodes for tuber-
culosis were done, of which almost 500 000 were done at 
sites where culture testing of sputum samples was a 
routine practice. After adjustment for age and sex, 
migrants reporting close or household contact with an 
individual with tuberculosis, applicants screened in 
countries with a WHO prevalence of 151–349 per 100 000, 
and those applying for settlement and dependant visas had 
an increased risk of being detected with bacteriologically 
conﬁ rmed tuberculosis. Although those reporting contact 
with a case of tuberculosis had high odds of active-
tuberculosis detection, the population attributable fraction 
was less than 3% in this group. These migrants are likely 
to beneﬁ t from early detection and treatment in their 
country of origin, and our ﬁ nding supports the role of 
contact tracing and investigation in the country of origin, 
in addition to increased coordination between pre-entry 
screening programmes and national tuberculosis 
programmes in the applicant’s country. 
Our study is the ﬁ rst comprehensive analysis of UK 
data for pre-entry screening of migrants, and we 
identiﬁ ed risk factors for tuberculosis in migrants 
screened before entry in several countries and estimated 
the number needed to screen to detect one case. The 
strengths of our study included the large dataset and its 
representativeness, resulting from a policy that required 
screening for all migrants applying to stay in the UK for 
more than 6 months. The UK technical instructions 
should reduce measurement error and misclassiﬁ cation 
bias for exposures and outcomes, including in the 
classiﬁ cation of chest radiographs because of the 
established system used. 
A limitation of this study is that it did not include data 
for undocumented migrants, refugees, and those with 
visas for less than 6 months. Undocumented migrants 
might be at a higher risk of tuberculosis than individuals 
in this study for complex reasons—eg, malnutrition, 
history of living in overcrowded situations such as 
refugee camps, higher rates of HIV, and a disruption in 
access to health services.14–16 However, these diﬀ erences 
might depend on the protocols determining access to 
health care for these migrants, as shown by the Israeli 
experience.17 Migrants who are planning to stay in the 
UK for more than 6 months, such as those in this study, 
are likely to be from higher socioeconomic backgrounds 
than average in their country of origin. 
Close or household contact with an individual with 
tuberculosis might be under-reported because visa 
applicants might suspect it would count against their 
application. If this is true, then we will have under-
estimated the magnitude of this risk factor. Unmeasured 
confounding (caused by variables not collected or 
adjusted for) might explain diﬀ erences between the 
prevalence seen in pre-entry screening and WHO popu-
lation estimates. The availability of confounding 
variables was scarce, since the data were collected for 
operational visa processing and not epidemiological 
analysis. We therefore believe that several factors, 
including bias and unmeasured confounding, could 
explain the ﬁ nding that tuberculosis detection was not 
the highest in applicants from countries with the 
highest WHO prevalence, and urge caution in the 
interpretation of this lack of trend in the UK pilot data 
and updated meta-analysis.
Our results might diﬀ er from published work on pre-
entry screening for several other reasons. First, the data 
presented are for migrants intending to stay for a 
minimum of 6 months. Second, a large proportion of 
migrants screened were students or young adults of 
working age, but no data were available from published 
studies that would allow adjustment of estimates. Third, 
not all published studies provide exact details of how 
culture testing was done, and the investigators of a large 
study8 highlighted the fact that the procedure might not 
have been uniform. In our study, consistent with UK 
technical instructions, cases could be bacteriologically 
Univariable OR Multivariable OR p value
Age (years)    
0–15 0·4 (0·2–0·8) 0·3 (0·1–0·6) <0·0001
16–44 1·0 1·0  ¨
45–64 1·4 (0·9–2·3) 1·2 (0·7–1·9) 0·49
≥65 4·0 (2·2–7.3) 3·3 (1·8–6.1) <0·0001
Sex    
Female 1·0 1·0 ··
Male 0·7 (0·6–0·8) 1·0 (0·9–1·3) 0·75
Close or household contact with an individual with tuberculosis  
No 1·0 1·0 ··
Yes 16·4 (10·4–26·0) 11·4 (7.0–18.4) 0·0011
Visa category    
Student 1·0 1·0 ··
Settlement and dependant 1·2 (1·0–1·5) 1·3 (1·1–1·6) 0·0104
Work 1·1 (0·7–1·7) 1·1 (0·7–1·8) 0·60
Working holiday maker 0·7 (0·4–1·4) 1·5 (0·8–2·8) 0·18
Family reunion 1·8 (0·8–3·8) 1·1 (0·5–2·5) 0·73
Other 0·6 (0·3–1·3) 0·8 (0·3–1·8) 0·54
WHO prevalence (per 100 000) of tuberculosis in country of screening  
40–149 0·1 (0·0–0·2) 0·1 (0·0–0·2) <0·0001
150–349 1·0 1·0 ··
≥350 0·3 (0·3–0·4) 0·3 (0·3–0·4) <0·0001
Sputum culture testing    
No 1·0 1·0 ··
Yes 2·4 (1·9–3·1) 2·4 (1·9–3·0) <0·0001
Data are OR (95% CI), unless otherwise indicated. OR=odds ratio.
Table 3: Risk factors for bacteriologically conﬁ rmed tuberculosis in all applicants screened, irrespective of 
whether culture testing of sputum was done, 2005–13
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conﬁ rmed by smear, culture, or both. Because of the UK 
technical instructions and quality assurance processes, 
such variability should not be an issue in our data. 
Finally, our study excluded duplicate screens in the 
analysis, which we believe previous studies did not 
undertake. 
Our analysis provides strong support for the previous 
change to US and UK technical instructions for the 
inclusion of culture testing in the screening protocol.13 
The groups of migrants identiﬁ ed as being at high risk of 
active tuberculosis will beneﬁ t from improved clinical 
outcomes and health status as a result of early detection 
and treatment, and the population will also beneﬁ t from 
reduced onward transmission.18–20 At present, students are 
not screened as part of the US pre-entry screening 
programme. Although their risk of tuberculosis is lower 
than many other groups, they remain a substantial source 
of cases, and our ﬁ ndings will enable further analyses, 
including updated analyses of the cost-eﬀ ectiveness of 
screening programmes for students.21 Delays introduced 
by the requirement for culture testing of sputum sample, 
which can take a minimum of 6 weeks in liquid media 
and 8 weeks in solid media, also pose concern—eg, such 
delays can result in students missing the beginning of the 
academic year or skilled migrants being delayed in 
starting work. New rapid tests with high sensitivity (eg, 
GeneXpert MTB/RIF system) are available and could 
potentially reduce these delays, but these tests should be 
assessed in the operational setting of pre-entry screening 
and compared with traditional culture methods before 
being widely rolled out.22,23
Migrants from low-prevalence countries were at a 
reduced risk of active tuberculosis. Countries that have 
pre-entry screening programmes invest public funds 
into the quality assurance of such screening, and 
therefore a threshold above which pre-entry screening is 
cost-eﬀ ective should be determined. The number needed 
to screen to detect one case across all sites in this pilot 
programme was 1087 and was reduced to 444 when only 
migrants from countries with prevalence of 150–349 per 
50–149 cases per 100 000 population
King 2009–10,8 Malaysia
King 2009–10,8 China
Aldridge 2007–13, Ghana
Summary estimate (I²=48·6%; p=0·143)
150−249 cases per 100 000 population
King 2009–10,8 South Korea
King 2009–10,8 Thailand
King 2009–10,8 Vietnam
Painter 2008–10,9 Vietnam
King 2009–10,8 Nepal
Aldridge 2007–13, Tanzania
Aldridge 2007–13, Sudan
Aldridge 2007–13, Thailand
Summary estimate (I²=97·9%; p<0·0001)
250−349 cases per 100 000 population
King 2009–10,8 India
King 2009–10,8 Indonesia
Maloney 1998–99,10 Vietnam
Malone 1991–93,11 Haiti
Aldridge 2007–13, Côte d’Ivoire
Aldridge 2007–13, Kenya
Summary estimate (I²=98·0%; p<0·0001)
≥350 cases per 100 000 population
Mor 2001–05,12 Ethiopia
King 2009–10,8 Philippines
Oeltmann 2004–05,13 Laos
King 2009–10,8 Cambodia
Aldridge 2007–13, Bangladesh
Aldridge 2007–13, Pakistan
Aldridge 2007–13, Somalia
Summary estimate (I²=94·0%; p<0·0001)
 62·2 (25·3–114·0)
 19·6 (10·5–31·3)
 10·7 (0·2–32·3)
 15·7 (7·8–25·7)
 18·8 (7·7–34·5)
 18·9 (0·3–56·8)
 315·7 (228·0–417·4)
 1049·8 (913·4–1195·5)
 174·8 (48·7–368·3)
 120·2 (33·4–253·3)
 24·9 (0·0–106·7)
 292·3 (244·5–344·3)
 192·1 (169·6–215·9)
 40·2 (25·6–58·1)
 0·0 (0·0–18·7)
 1298·1 (1117·6–1491·8)
 336·4 (236·1–454·0)
 1·0 (0·0–182·7)
 101·1 (52·6–164·6)
 126·0 (105·1–148·7)
 276·6 (194·1–373·3)
 336·1 (242·7–444·4)
 368·8 (279·0–471·0)
 661·4 (306·1–1142·2)
 76·9 (63·2–92·0)
 52·2 (43·5–61·7)
 145·1 (30·6–330·1)
 71·7 (63·5–80·3)
Study, years screened, country of origin Yield (95% CI)
0 250 500 750 1000 1250 1500
Yield per 100 000 screened
Figure 3: Forest plot of prevalence of culture-positive cases of tuberculosis at pre-entry screening, stratiﬁ ed and sorted by WHO prevalence of tuberculosis in 
country of origin8–13
Articles
www.thelancet.com/infection   Vol 16   August 2016 969
100 000 population were screened. Several costs were 
associated with this pilot screening programme, 
including initial set-up costs funded by the UK 
Government (£1·1 million at November, 2010, prices) 
and the cost to individual applicants, which varied across 
sites but was around US$50–70 in November, 2011.24 
Therefore, a cost-eﬀ ective analysis that considers these 
and other relevant costs is strongly recommended. The 
analysis should also examine diﬀ erent perspectives, 
including that of the receiving country, wider society, and 
an enlightened self-interest approach in which there is 
investment in tuberculosis control programmes overseas 
by a receiving country.25,26
Risk factors for progression to active tuberculosis need 
to be identiﬁ ed, and rates of progression in those who 
tested negative before entry should be estimated. These 
data would be particularly useful in informing the 
possible eﬀ ect of the introduction of pre-entry screening 
for latent tuberculosis.27 Unmeasured confounding 
factors, including socioeconomic and HIV status, could 
be important, and eﬀ orts should be made to obtain 
relevant data in an appropriately sensitive manner, 
compliant with information governance and public 
health legislation. 
We identiﬁ ed several groups of migrants at high risk of 
active tuberculosis at pre-entry screening. To tackle the 
burden of disease in this population, a wide-ranging 
approach that includes screening and treatment for 
latent tuberculosis infection is necessary;9 however, 
migrants will remain at higher risk than those born in 
the UK because of an increased likelihood of exposure to 
infectious cases in the UK or when travelling back to 
their country of origin.28 The inclusion of latent-
tuberculosis screening at one point in time would not 
eliminate this risk, and a more comprehensive approach 
should therefore be explored. This approach could 
include improved integration between pre-entry 
screening and health services after arrival, and 
appropriate delivery of health care and health improve-
ment programmes, rather than focusing solely on 
tuberculosis. Such an approach would be welcomed, in 
view of the documented issues migrants have in 
accessing health services after arrival in the UK.29 
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